Spots Global Cancer Trial Database for pancreatic adenocarcinoma
Every month we try and update this database with for pancreatic adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis | NCT03152487 | Pancreatic Carc... Pancreatic Aden... Pancreatic Neop... Pancreatic Canc... Pancreatic Canc... | Celiac Plexus N... Radiofrequency ... | 19 Years - | AdventHealth | |
| Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma | NCT01129167 | Pancreatic Canc... | 18 Years - 85 Years | Columbia University | ||
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | NCT03816358 | Pancreatic Aden... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | Anetumab Ravtan... Biopsy Biospecimen Col... Gemcitabine Hyd... Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) in Focal Pancreatic Masses | NCT01315548 | Adenocarcinoma ... Chronic Pancrea... | 18 Years - 90 Years | University of Medicine and Pharmacy Craiova | ||
| Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms | NCT03435770 | Pancreatic Canc... Pancreatic Neop... Pancreatic Aden... Pancreatic Neur... Pancreatic Duct... | EUSRA RFA needl... | 21 Years - 99 Years | Singapore General Hospital | |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | NCT06440005 | Cancer Advanced Cancer Locally Advance... Metastatic Soli... Triple Negative... Pancreas Cancer Pancreatic Aden... | AGX101 | 18 Years - | Angiex, Inc. | |
| Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | NCT06119217 | Pancreatic Canc... | TTX-030, nab-pa... TTX-030, budiga... Nab-Paclitaxel ... | 18 Years - | Trishula Therapeutics, Inc. | |
| Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies | NCT04361708 | Pancreatic Aden... Gastroesophagea... Adenocarcinoma | Oxaliplatin Docetaxel Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | University of Chicago | |
| Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | NCT02749136 | Pancreatic Aden... | Preoperative mo... | 19 Years - | Asan Medical Center | |
| A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors | NCT03592264 | Solid Tumor Pancreatic Aden... | OBI-3424 | 18 Years - | OBI Pharma, Inc | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| Project Survival-Prospective Biomarker Discovery | NCT02781012 | Pancreatic Neop... Pancreatic Canc... Pancreatitis Pancreatic Aden... Metastatic Panc... | 18 Years - | Pancreatic Cancer Research Team | ||
| Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer | NCT01674556 | Pancreatic Aden... | Gemzar | - | Haukeland University Hospital | |
| Multicenter Trial of ESK981 in Patients With Select Solid Tumors | NCT05988918 | Pancreatic Aden... Adenosquamous C... Pancreatic Neur... Pancreatic Neur... Gastrointestina... Gastrointestina... Neuroendocrine ... | ESK981 | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | NCT05769959 | Renal Cell Carc... Non-small Cell ... Pancreatic Aden... Colorectal Canc... Ovarian Neoplas... | RO7515629 tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | NCT02345460 | Pancreatic Aden... Poorly Differen... Resectable Panc... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Undifferentiate... | Irinotecan Hydr... Oxaliplatin Leucovorin Calc... Fluorouracil Laboratory Biom... | 18 Years - 75 Years | Case Comprehensive Cancer Center | |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | NCT05877599 | Non-small Cell ... Head and Neck S... Colorectal Carc... Pancreatic Aden... Breast Cancer Other Solid Tum... | Autologous, eng... | 18 Years - | Neogene Therapeutics, Inc. | |
| Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | NCT04548752 | Metastatic Panc... Pancreatic Aden... Stage IV Pancre... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer | NCT02174887 | Pancreatic Aden... | Nab-paclitaxel ... | 18 Years - | Institut Paoli-Calmettes | |
| Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency | NCT04098237 | Pancreatic Aden... | Pancrelipase | 18 Years - | Cedars-Sinai Medical Center | |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | NCT04498689 | Metastatic Panc... | Camrelizumab Nab paclitaxel Gemcitabine Inj... | 18 Years - 75 Years | Fudan University | |
| Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC | NCT03665441 | Pancreatic Aden... | eryaspase Gemcitabine plu... Irinotecan plus... | 18 Years - | ERYtech Pharma | |
| PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC | NCT06396637 | Pancreatic Aden... | Sapropterin Dih... | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | NCT05737706 | Solid Tumor Advanced Solid ... Non-small Cell ... Colo-rectal Can... Pancreatic Aden... | MRTX1133 | 18 Years - | Mirati Therapeutics Inc. | |
| Prospective Validation of an EHR-based Pancreatic Cancer Risk Model | NCT05973331 | Pancreatic Aden... Predictive Canc... | Pancreatic Canc... | 40 Years - 100 Years | Beth Israel Deaconess Medical Center | |
| Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion | NCT05245500 | Mesothelioma Non Small Cell ... Malignant Perip... Solid Tumor Pancreatic Aden... Advanced Solid ... | MRTX1719 | 18 Years - | Mirati Therapeutics Inc. | |
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | NCT01959672 | Pancreatic Aden... Resectable Panc... Stage I Pancrea... Stage IA Pancre... Stage IB Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | 4-Dimensional C... Fluorouracil Gemcitabine Hyd... Laboratory Biom... Leucovorin Calc... Nelfinavir Mesy... Oregovomab Stereotactic Bo... Therapeutic Con... | 19 Years - | University of Nebraska | |
| Endoscopic Ultrasound Elastography in Pancreatic Masses | NCT00909103 | Pancreatic Aden... Chronic Pancrea... | 18 Years - 80 Years | University of Medicine and Pharmacy Craiova | ||
| Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) | NCT03415854 | Pancreatic Canc... Pancreatic Duct... Pancreatic Aden... Pancreas Metast... Adenocarcinoma | Paricalcitol (Z... | 18 Years - | HonorHealth Research Institute | |
| EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma | NCT03772756 | Pancreatic Aden... | Endoscopic ultr... chemoradiothera... | 20 Years - 80 Years | First People's Hospital of Hangzhou | |
| Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma | NCT01474564 | Pancreatic Aden... | Blood draw | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | NCT02427841 | Pancreatic Aden... Resectable Panc... | Fluorouracil Gemcitabine Image Guided Ra... Intensity-Modul... Laboratory Biom... Nab-paclitaxel Therapeutic Con... | 18 Years - | OHSU Knight Cancer Institute | |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma | NCT03250273 | Metastatic Chol... Cholangiocarcin... Pancreatic Canc... Metastatic Panc... Unresectable Pa... Unresectable Ch... | Entinostat Nivolumab Entinostat Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of ASP2138 in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, Pancreatic Cancer | NCT05365581 | Gastric Adenoca... Gastroesophagea... Pancreatic Aden... | ASP2138 | 18 Years - | Astellas Pharma Inc | |
| Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma | NCT01765036 | Pancreatic Aden... | SonoVue® | 18 Years - | Société Française d'Endoscopie Digestive | |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | NCT00769483 | Pancreatic Canc... Pancreatic Aden... | MK-0646 Gemcitabine Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Intermittent Suction Technique in the Diagnosis of Pancreatic Solid Lesions | NCT03829748 | Pancreatic Canc... Pancreatic Neop... | Intermittent as... | 18 Years - | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | |
| Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | NCT04992507 | Pancreatic Aden... | Anesthesia Proc... General Anesthe... Resection | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | NCT03715933 | Solid Tumors Malignant Pleur... Gastric Adenoca... Colorectal Aden... Sarcoma Pancreatic Aden... Ewing Sarcoma Chondrosarcoma GIST SDH-deficient S... | INBRX-109 Carboplatin Cisplatin Pemetrexed 5-fluorouracil Irinotecan Temozolomide | 12 Years - 85 Years | Inhibrx Biosciences, Inc | |
| Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer | NCT01389440 | Pancreatic Aden... | Gemcitabine and... | 18 Years - 75 Years | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | NCT01660711 | Pancreatic Aden... | 5 Fluorouracil Leucovorin Irinotecan Oxaliplatin | 18 Years - | NorthShore University HealthSystem | |
| mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma | NCT04986930 | Pancreatic Aden... Pancreatic Canc... | SBRT+mFOLFIRINO... mFOLFIRINOX | 19 Years - | Asan Medical Center | |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | NCT03468244 | Advanced Esopha... Gastric Adenoca... Pancreatic Aden... Colorectal Aden... | Personalized mR... | 18 Years - 75 Years | Changhai Hospital | |
| A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advanced Pancreatic Cancer | NCT05657743 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... Pancreatic Aden... | Radiation: Diff... | 18 Years - | Alpha Tau Medical LTD. | |
| Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | NCT03376659 | Metastatic Colo... Colorectal Aden... Pancreatic Aden... Metastatic Panc... | Durvalumab CV301 Capecitabine Bevacizumab | 18 Years - | Georgetown University | |
| Identifing Risk Factors for Pancreaticojejunostomy Leakage Following Pancreaticoduodenectomy | NCT04798560 | Pancreatic Fist... Whipple Operati... Pancreaticoduod... POPF | Pancreaticoduod... | 18 Years - | University of Athens | |
| Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer | NCT02174887 | Pancreatic Aden... | Nab-paclitaxel ... | 18 Years - | Institut Paoli-Calmettes | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) | NCT02707328 | Pancreas Cancer Pancreatic Canc... Adenocarcinoma ... Pancreas Adenoc... Pancreatic Aden... | Gemcitabine nab-paclitaxel CyberKnife | 18 Years - | The Cooper Health System | |
| Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer | NCT04406571 | Pancreatic Aden... | Data record | 18 Years - | CHU de Reims | |
| High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | NCT02757859 | Acinar Cell Car... Ampulla of Vate... Cholangiocarcin... Duodenal Adenoc... Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Periampullary A... | Pancreatectomy Lavage Pancreatectomy Lavage Pancreatectomy | 18 Years - | Thomas Jefferson University | |
| KEBI-Cyto Study - Use of the Biocartis Idylla | NCT04236102 | Pancreatic Aden... Lung Cancer | Biocartis Idyll... | 18 Years - | Royal Cornwall Hospitals Trust | |
| Repeated EUS-guided Fine Needle Biopsy of Pancreatic Masses After Non-diagnostic or Inconclusive Results | NCT05226572 | Pancreatic Aden... Pancreas Cancer Pancreas Metast... | endoscopic ultr... | 18 Years - 90 Years | University of Bologna | |
| Namodenoson Treatment of Advanced Pancreatic Cancer | NCT06387342 | Pancreatic Aden... Pancreatic Canc... | Namodenoson 25m... | 18 Years - | Can-Fite BioPharma | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida | |
| Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy | NCT06135649 | Pancreas Cancer Pancreatic Aden... | Systematic lymp... | - | Universita di Verona | |
| NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer | NCT01369420 | Pancreatic Aden... | NanoKnife Low E... | 18 Years - | Angiodynamics, Inc. | |
| TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma | NCT04923529 | Pancreas Cancer | TAS 102 | 18 Years - 75 Years | The University of Hong Kong | |
| Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally Advanced Pancreatic Cancer | NCT06026943 | Pancreatic Canc... Unresectable Pa... Pancreatic Aden... | DaRT seeds inse... | 18 Years - 120 Years | Alpha Tau Medical LTD. | |
| The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer | NCT05752812 | Pancreatic Aden... | 18 Years - 99 Years | Medical University of Vienna | ||
| Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients. | NCT04652206 | Metastatic Panc... Locally Advance... Inoperable Dise... Localized Pancr... | SCO-101 Gemcitabine Nab paclitaxel | 18 Years - | Scandion Oncology A/S | |
| High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery | NCT02757859 | Acinar Cell Car... Ampulla of Vate... Cholangiocarcin... Duodenal Adenoc... Pancreatic Aden... Pancreatic Duct... Pancreatic Intr... Periampullary A... | Pancreatectomy Lavage Pancreatectomy Lavage Pancreatectomy | 18 Years - | Thomas Jefferson University | |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | NCT03816358 | Pancreatic Aden... Stage II Pancre... Stage III Pancr... Stage IV Pancre... | Anetumab Ravtan... Biopsy Biospecimen Col... Gemcitabine Hyd... Ipilimumab Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | NCT03856658 | Pancreatic Aden... Liver Metastase... | Floxuridine (FU... Hepatic Artery ... Heparinized Sal... | 18 Years - 75 Years | Spectrum Health Hospitals | |
| Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue | NCT03140592 | Pancreatic Canc... Pancreatic Aden... Pancreatic Cyst | Biopsy | 18 Years - | Stony Brook University | |
| PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer | NCT04119362 | Pancreatic Aden... | Quality of live... Optional transl... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") | NCT01726582 | Pancreatic Aden... | Milestone 1: Ta... Milestone 2: Ch... Milestone 3: Ta... Milestone 3: Ch... Milestone 4: st... Milestone 4: Ch... Milestone 5: Ta... Milestone 5: Ch... Milestone 6: Ge... Milestone 6: Ch... Milestone 7: Ch... Milestone 8: Ta... Milestone 9: Ge... Milestone 10: N... | 18 Years - | Medical College of Wisconsin | |
| Assessment of What Patients and Healthcare Providers Value | NCT04483349 | Gastric Adenoca... Pancreatic Aden... Pancreatic Neur... | Survey Administ... | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | NCT02045589 | Pancreatic Aden... Metastatic Panc... | VCN-01 Gemcitabine Abraxane® | 18 Years - | Theriva Biologics SL | |
| mFOLFIRINOX With or Without Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma | NCT04986930 | Pancreatic Aden... Pancreatic Canc... | SBRT+mFOLFIRINO... mFOLFIRINOX | 19 Years - | Asan Medical Center | |
| GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES | NCT06102889 | Pancreatic Aden... | liquid biopsy | 18 Years - | Karolinska University Hospital | |
| Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | NCT02349867 | Pancreatic Aden... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Recurrent Pancr... | Gemcitabine Sorafenib Vorinostat 3-Dimensional C... Intensity-Modul... RosetteSep DEPfff | 18 Years - | Virginia Commonwealth University | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer | NCT03401827 | Pancreatic Aden... Chemotherapy Ef... | Chemotherapy (G... | 20 Years - | Seoul National University Hospital | |
| Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | NCT03468244 | Advanced Esopha... Gastric Adenoca... Pancreatic Aden... Colorectal Aden... | Personalized mR... | 18 Years - 75 Years | Changhai Hospital | |
| RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | NCT03745430 | Pancreatic Aden... | Ramucirumab | 18 Years - | Hellenic Cooperative Oncology Group | |
| Assessment of What Patients and Healthcare Providers Value | NCT04483349 | Gastric Adenoca... Pancreatic Aden... Pancreatic Neur... | Survey Administ... | 18 Years - | M.D. Anderson Cancer Center | |
| Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma | NCT04662112 | Pancreatic Canc... Pancreatic Duct... | NASOX | 19 Years - | Asan Medical Center | |
| Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | NCT03856658 | Pancreatic Aden... Liver Metastase... | Floxuridine (FU... Hepatic Artery ... Heparinized Sal... | 18 Years - 75 Years | Spectrum Health Hospitals | |
| A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma | NCT03483038 | Pancreatic Aden... | Liposomal Irino... FOLFOX regimen | 18 Years - 99 Years | University of Florida |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
